(BW) (IMMUNE-RESEARCH)(IMM.) Immune Network Research: Second Phase 1F7 mAb Study in Progress

(BW) (IMMUNE-RESEARCH)(IMM.) Immune Network Research: Second Phase 1F7 mAb Study in Progress

BUSINESS WIRE; May 11, 1998

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--May 11, 1998-- IMMUNE RESEARCH (VSE:IMM.) At the request of the Vancouver Stock Exchange the Company reports that the study of its proprietary monoclonal antibody 1F7 in infected macaque monkeys as a model of HIV disease is in progress and there are no material changes in the Company. The study now involves nine macaques, seven of which are infected with SHIV 89.6P and is on day 31 of a protocol which continues to October with blood and tissue samples being taken and cryogenically preserved for analysis.

The study, announced April 14, is evaluating the effectiveness of 1F7 mAb as an adjuvant or therapeutic for human infection related to the AIDS virus and the macaques have received a series of five injections of mAb 1F7. This research is funded under a strategic partnership between the Company and Immpheron, Inc., of Lexington, KY, to continue research and development following earlier promising findings in the effectiveness of mAb 1F7.

The encouraging results of the Company's previous study leading to this live animal study on mAb 1F7 were published in the prestigious "Proceedings of the National Academy of Science USA" (PNAS Vol. 95 pp. 276-281, January 6, 1998). In that study, mAb 1F7 injection increased the breadth and potency of virus neutralizing antibodies in all three monkeys chronically infected with SHIV-IIIB. No such changes occurred in a SHIV-IIIB-infected monkey with an isotype control antibody. The PNAS paper and information on the Company can be found through the Company's web site http://www.stockgroup.com/IMM.html.

Victor J. E. Jones, President

The Vancouver Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

--30--mjb/clv*

CONTACT: Immune Network Research Ltd. Victor J. E. Jones, 604/689-3923 604/684-5854 (FAX) http://www.stockgroup.com/imm.html

Copyright (c) 1998/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
980511
BW980504

Copyright © 1998 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .